Effects of electroacupuncture therapy for depression: study protocol for a multi-centered, randomized controlled trial

CURRENT STATUS: UNDER REVIEW

Wa Cai  
Shanghai University of Traditional Chinese Medicine

Wen Ma  
Shuguang Hospital

Ai-Wen Chen  
Shuguang Hospital

Wei-Dong Shen  
shenweidong_1018@163.com

Corresponding Author
ORCiD: 0000-0003-0959-1030

DOI:
10.21203/rs.2.12198/v1

SUBJECT AREAS
Internal Medicine  Integrative & Complementary Medicine

KEYWORDS
Electroacupuncture therapy; depression; protocol; multi-centered; randomized controlled trial
Abstract

Background

As a major public health problem, depression has a negative impact on individuals and society. The aim of this well-designed trial is to evaluate the efficacy and safety of electroacupuncture (EA) treatment for depression.

Methods/Design

A three-arm parallel, non-blinded, randomized controlled trial was performed in four hospitals (centers). 144 participants will be divided into three groups: electroacupuncture (EA) group, hand acupuncture (HA) group and western medicine group. Participants in EA group and HA group received 12 sessions of acupuncture treatment for 4 weeks. Participants allocated to western medicine group will only take 20mg fluoxetine orally per day for 4 weeks. The primary outcome is Hamilton Depression Scale (HAMD). Secondary outcomes are Self-Rating Depression Scale (SDS), Depression Scale of traditional Chinese medicine (Depression Scale of TCM), brain fMRI and blood biomarkers including neurotransmitters 5-HT, DA, NE, inflammatory cytokines IL-1β, TNF-α, IL-6 and neurotrophin BDNF. All the outcomes will be assessed at baseline, 4 weeks after EA treatment onset and 6-month follow-up.

Discussion

The results of this trial will verify the efficacy and safety of EA treatment for depressive patients and provide acupuncturists and clinicians with robust clinical evidence.

Background

Characterized by emotional, behavioral and cognitive features, symptoms of depression include dysphoric mood, feelings of hopelessness, loss of interest, social withdrawal, eating disorder, insomnia, fatigue, low self-esteem and poor concentration. As a major
public health problem, depression has a negative impact on individuals and society. A recent meta-analysis\textsuperscript{[1]} benchmarking the prevalence of depression in the community from 30 countries between 1994 and 2014 reported that the one-year and lifetime prevalence of depression was 7.2% and 10.8% respectively. Depression is associated with impaired physical or mental function\textsuperscript{[2]} and a substantial role loss in social life\textsuperscript{[3]}. It was found to have a worse impact on quality of life when compared with chronic diseases such as hypertension or diabetes\textsuperscript{[4]}. Furthermore, health services for depressed patients bring about considerable financial costs\textsuperscript{[5]}. In most cases, depressed patients are treated with antidepressants\textsuperscript{[6]} such as citalopram, escitalopram, nortriptyline, milnacipran, mirtazapine, piracetam and fluoxetine. Whereas, antidepressants have many side effects such as nausea, fatigue, insomnia, dry month, blurred vision, constipation, sexual problems\textsuperscript{[7]}. It was reported that Australians and Americans with depression had a preference for complementary therapies\textsuperscript{[8-10]}. Based on the theory of Traditional Chinese Medicine (TCM), acupuncture has a long history of use. Since that electroacupuncture (EA) was reported to effectively reduce depressive behaviours with few side effects\textsuperscript{[11]}, studies have found that EA can regulate neurotransmitter levels of serotonin (5-HT), noradrenaline (NE) and dopamine (DA) in animal models of depression\textsuperscript{[12]}. EA has been verified to trigger functional magnetic resonance imaging (fMRI) changes in the default mode network, anterior cingulate cortex and amygdala-hippocampal formation\textsuperscript{[13, 14]} where dysfunction has been previously detected in depressive disorders\textsuperscript{[15]}. Inflammatory cytokines including IL–1β, TNF-α and IL–6 were found to be changed in patients with depression treated by EA\textsuperscript{[16]} which was also capable of affecting neurotrophin levels of BDNF in depressed rats\textsuperscript{[17]}. 
However, a recent Cochrane meta-analysis\textsuperscript{[18]} focusing on the effectiveness of acupuncture or EA treatment for depression revealed that acupuncture or EA’s effect compared with medication in reducing depression severity was unclear owing to the very low quality of evidence. Considering most trials did not report adverse events (AE), the risk of AEs with acupuncture or EA was also uncertain. Besides, few studies included follow-up assessment. Thus, a high-quality randomized controlled trial (RCT) is urgently needed. This protocol has been designed to conduct a multi-centered, randomized controlled trial to assess the clinical efficacy and safety of EA for depression.

Methods/design

Study design

According with the Consolidated Standards of Reporting Trials\textsuperscript{[19]} and Standards for Reporting Interventions in Clinical Trials of Acupuncture guidelines for acupuncture studies\textsuperscript{[20]}, a multi-centered, parallel, randomized controlled trial will be conducted from June 2019 to June 2021 (Fig. 1). Fig. 2 indicates the study schedule for enrollment, treatments, outcome measurements and data collection. The SPIRIT checklist can be found in Additional file 1.

Participants

Patient screening

In order to conduct the safety assessment of patients and exclude patients with fatal conditions such as renal failure, heart failure, hepatic impairment, patient screening will be done by history inquiry, history recording and laboratory test which includes complete blood count (CBC), urinalysis, fecal analysis, electrocardiograph (ECG), function of kidney, liver and thyroid.

Inclusion criteria
Patients who meet the following criteria will be enrolled in the trial: meet the diagnostic criteria according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition\cite{21}; aged 18~75 years old, males or females; scores of Hamilton Depression Scale 17 (HAMD-17) are over 17; able to understanding and answering the questions of scales; willing to sign informed consents.

**Exclusion criteria**

Patients who meet any of the following criteria will be excluded from the trial: undergoing other anti-depressive treatments within 1 month; history of personality disturbance, psychiatric disorders or brain diseases; complications of severe heart failure, infectious diseases or immune deficiency; severe depression with suicide thoughts; unable or unwilling to finish the whole trial.

**Elimination criteria**

Patients who meet any of the following criteria after treatment will be eliminated from the trial: occurrence of severe AEs; aggravation of depression severity; poor compliance.

**Recruitment strategies**

Participant recruitment will take advantage of several strategies. Participants in this RCT will be mainly recruited from Shanghai Shuguang Hospital, Shanghai Ruijin Hospital, Shanghai Renji Hospital and Shanghai Yueyang Hospital. Posters which will be put up in those four hospitals include brief introductions about the purpose, procedures, free treatments, possible risks of the trial and researchers’ contact information. After screening test, another researcher will assign those participants who have signed the consent forms to different intervention groups. The recruitment process will be conducted by a clinical recruitment staff.

**Randomization and allocation**

A computer program (Strategic Applications Software (SAS), version 9.1.3 (SAS Institute
Inc., Cary, NC, USA) was used by a statistician to generate the random allocation sequence. Four hospitals will be chosen as strata by using a stratified block randomization scheme. Opaque envelopes were used to seal generated sequences and delivered to each center. Having enrolled participants who met the selection criteria, the researcher opened the random allocation envelope in front of each participant one by one and assigned him to 1 of 3 groups.

Blinding

This study was nonblinded.

Interventions

The enrolled participants were allocated into three groups: electroacupuncture (EA) group, hand acupuncture (HA) group or western medicine group.

Participants in EA group and HA group received 12 sessions of acupuncture treatment for 4 weeks, 3 times a week by experienced acupuncturists to ensure identical acupuncture treatment according to the SOPs using stainless steel disposable needles (Energy, 40mm in length and 0.25mm in diameter, Jiajian Medical Supplies Co Ltd, Jiangsu, China). The same acupoints will be selected for participants in these two acupuncture groups. After skin sterilization, acupuncturists will puncture DU20, DU24 and GB8 horizontally 8 mm into the scalp skin. LR3, LI4, GB20, LI11, KI3, GB34, ST36 will be punctured vertically 15 mm into the skin, and only PC6 will be punctured 8 mm into the skin vertically to keep off the median forearm nerve. Needle manipulation including lifting, thrusting, and rotating will be done to obtain needling sensation (de-qi sensation). Acupoints of DU20, DU24 and bilateral ST36 will be stimulated using an electric current at a frequency of 2/15 Hz by EA device (Hwato, SDZ-II, Suzhou Medical Supplies Co Ltd, Jiangsu, China) in EA group, while EA device will not be used in HA group. The needle retention time for both two
acupuncture groups will be 30 min for each session.

Participants allocated to western medicine group will only take 20mg fluoxetine orally per day for 4 weeks instead of receiving acupuncture treatment.

Outcome

Primary outcome

The primary outcome of the clinical study will be the score changes of Hamilton Depression Scale (HAMD) between baseline, 4 weeks after EA treatment onset and 6-month follow-up.

Hamilton Depression Scale (HAMD)

The HAMD is a doctor-rated questionnaire designed to assess depression severity by rating multiple dimensions including probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms with a score on a 3 or 5 point scale\[^{[22]}\]. A score of 0–7 is considered to be “normal”, while scores of 20 or higher indicate “moderate or severe depression”. The assessment time is 20 minutes\[^{[23]}\].

Secondary outcomes

Secondary outcomes will be scored at the same time points as primary outcome, including Self-Rating Depression Scale (SDS), Depression Scale of traditional Chinese medicine (Depression Scale of TCM), brain fMRI and blood biomarkers.

Self-Rating Depression Scale (SDS)

Designed to assess depression severity for patients diagnosed with depression\[^{[24]}\], the SDS is a short self-rated questionnaire consisting of 30 items that rate the affective, psychological and somatic symptoms associated with depression. Each item is scored on a scale of 1~4. Depression severity is classified into “normal” (score 20~44), “mild” (score
Depression Scale of traditional Chinese medicine (TCM)

Based on the theory of TCM, the depression scale of TCM includes 6 items concerning depression-related symptoms such as chest distress, belching, palpitation, insomnia, fatigue, irritability and weeping. Each item is scored on a 0~3 scale. Higher summed scores indicate severer symptoms of depression from the perspective of TCM.

Brain fMRI

A General Electric (GE) signa 1.5T echo speed superconducting MRI scanner will be used to perform the fMRI measurements. Functional images will be acquired with an echo-planar imaging (EPI) sequence. During the resting-state fMRI acquisition, each participant will be required not to think of anything and keep their eyes closed without falling asleep for 4.5 minutes’ fMRI scanning. Statistical Parametric Mapping (SPM12), Resting-State fMRI Data Analysis Toolkit (REST), and Data Processing Assistant for Resting-State fMRI (DPARSF) will be used to conduct the preprocessing of fMRI data. First, the remaining images will be corrected for different slice acquisition timing and head motion. Second, the images will be spatially normalized to the standard EPI template in SPM12 and resampled to a voxel size of 3×3×3 mm³. Third, the images will be smoothed with an isotropic Gaussian kernel (FWHW = 4 mm) and temporal band-pass filtered (0.01 Hz–0.08 Hz). Finally, the Automated Anatomical Labeling (AAL) atlas will be used to segment brain signals¹²⁶. 116 brain regions and 144 volumes will be obtained after preprocessing.

Blood biomarkers

Blood samples of participants will be collected and clot for at least 30 minutes at room temperature and centrifuged at 3,000 rpm for 10 minutes at 4 °C. Obtained serum
samples will be stored at –80 °C until the day of enzyme-linked immunosorbent assay (ELISA) experiment. Serum 5-HT and BDNF will be measured using ELISA kits from R&D Systems (Minneapolis, USA). Serum NE and DA will be measured using ELISA kits from Weiao Co., Ltd. (Shanghai, China). IL-6, TNF-α and IL-1β levels in serum will be measured using ELISA kits from Xitang Co., Ltd. (Shanghai, China).

Safety assessment

During the whole treatment, participants safety will be assessed to avoid adverse events (AEs). AEs of acupuncture mainly include local bleeding or pain, local redness or bruising, itching and dizziness, while fluoxetine will bring about a series of AEs such as nausea, upset stomach, constipation, headaches, insomnia. A researcher will record the time of occurrence, severity, progress and treatment of AEs at each visit. Once any severe AE occurs, both the principal investigator and the institutional review board (IRB) will be informed and take prompt actions simultaneously.

Sample size

The data statistician will be responsible for the calculation of the required sample size in each group. Based on previous studies, the cure effects of EA, hand acupuncture and western medicine for depression were 15.7%, 17.4% and 2.9% respectively. Considering a significance level of 0.05 and a statistical power of 0.9, the calculated sample size in total is 120. Assuming about a 20 % drop rate at a 1:1:1 allocation ratio, 144 participants should be recruited in this trial with 36 for each group.

Data collection, management and monitoring

Baseline characteristic data will be collected, which consist of name, age, gender, employment, highest education level, diagnosis, typical symptoms, frequency of symptom occurrence, previous treatment and family history. Outcomes will be assessed at baseline,
4 weeks after EA treatment onset and 6-month follow-up. In each research center, original forms including case report forms (CRF) and Adverse Events Form will be carefully checked and input into the computer. The trial will be monthly monitored by the Data and Safety Monitoring Board (DSMB) of four centers. The data manager of the DSMB from each center has the right to access the final data set and approve others' requests of accessing the final data set.

**Statistical analysis**

SPSS 24.0 (SPSS Inc., Chicago, IL, USA) will be used to conduct the whole data analysis. The intention-to-treat (ITT) analysis will include any participant who has at least one treatment session. The “last observation carried forward” rule will be applied to manage missing data in ITT analysis of secondary outcomes, while the maximum likelihood estimation method will be used for primary outcome. Any participant who receives at least nine treatment sessions during the trial will be included in per protocol (PP) analysis. Considering the homogeneity of the baseline characteristics between groups, group t-test for quantitative data and $\chi^2$ test for qualitative data will be applied. Group t test for normally distributed data or Mann-Whitney $U$ test for non-normally distributed data will be used to compare variables between groups. For differences within each group, repeated measured ANOVA will be used to analyze assessments of different time points, while Wilcoxon signed-rank test will be selected for non-normally distributed data. A P value $<0.05$ will be considered statistically significant (two-sided).

**Clinical trial registration**

This RCT has been applied for registration in the Chinese Clinical Trial Registry (ChiCTR1900023420, http://www.chictr.org.cn).

**Discussion**
EA has been found to be effective in treating with depression with few side effects in a number of clinical studies[27-30], but an updated Cochrane review[18] concluded that there was lack of solid evidence to recommend that EA is a beneficial treatment for depressive patients in many aspects due to poor quality of previous trials, which required further high quality trials to support the recommendation. Besides, fluoxetine, as a selective serotonin reuptake inhibitor (SSRI), is a widely used antidepressant. It was found to be effective in treating depression[31]. This RCT is designed to compare the difference results of intervention by EA, hand acupuncture and fluoxetine to evaluate the efficacy of EA in treating depression and provide reliable clinical evidence.

The strengths of this RCT are associated with its multi-centered design, concealed randomization, scales of multiple dimensions, imageological changes, specific biomarkers to better evaluating EA’s efficacy. Based on the theory of TCM, the combination of acupoints DU20, DU24, GB8, LR3, LI4, GB20, LI11, KI3, GB34, ST36 and PC6, most frequently used for treating depression, can alleviate depressive symptoms by dispersing liver qi and relieving qi stagnation.

However, limitations in this trial should also be noted. It is unfeasible to blind the acupuncturists or clinicians who will treat participants from three groups differently. Meanwhile, participants allocated to different groups will definitely accept different treatments. Thus, participants cannot be blinded either. Double blinding is hard to be performed in this RCT.

As a conclusion, according to the CONSORT[19] and STRICTA[20] guidelines, the aim of this trial is to provide acupuncturists and clinicians with robust evidence of the efficacy and safety of EA treatment for depressive patients.

Trial status
The protocol version number is 02 (30 June 2018). The trial is under participant recruitment. The recruitment began on 3 June 2019. The approximate date when recruitment will be completed is 30 December 2020.

Abbreviations

RCT: randomized controlled trials; 5-HT: serotonin;
NE: noradrenaline; DA: dopamine;
CBC: complete blood count; ECG: electrocardiograph;
HAMD: Hamilton Depression Scale; SDS: Self-Rating Depression Scale;
AE: adverse event; IRB: institutional review board;
ITT: intention-to-treat; DSMB: Data and Safety Monitoring Board;

Declarations

Ethics approval and consent to participate

Central ethical approval has been confirmed from the Ethics Committee of Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine (ref approval No. 2019-675-30-01) and we will not begin recruiting at other centres in the trial until local ethical approval has been obtained. The purpose, procedures and potential risks of the trial will be explained to the participants in advance. All participants should sign on the informed consent before taking part in the trial.

Competing interests

The authors declare that they have no competing interests.

Author’s contributions

The trial was designed by MW, CAW and CW. CW drafted the manuscript, which was carefully revised and discussed by MW and SWD. All authors read and approved the final manuscript.
Availability of data and material
Not applicable.

Acknowledgements
Not applicable.

Funding
This research was funded by Shanghai Committee of Science and Technology, China (Grant No. 18401970601). The funding body approved the design of the study and this manuscript. It will monitor the collection, analysis, and interpretation of data.

Consent for publication
Not applicable.

Author details

1Institute of acupuncture and anesthesia, Shanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

2Department of acupuncture, Shanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

References

[1] Lim G Y, Tam W W, Lu Y, et al. Prevalence of Depression in the Community from 30 Countries between 1994 and 2014 [J]. Scientific reports, 2018, 8(1): 2861.

[2] Hays R D, Wells K B, Sherbourne C D, et al. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses [J]. Archives of general psychiatry, 1995, 52(1): 11-19.

[3] Kessler R C, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) [J]. Jama, 2003, 289(23): 3095-3105.
[4] Spitzer R L, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study [J]. Jama, 1995, 274(19): 1511-1517.

[5] Thomas C M, Morris S. Cost of depression among adults in England in 2000 [J]. The British journal of psychiatry: the journal of mental science, 2003, 183(514-519).

[6] Goldman L S, Nielsen N H, Champion H C. Awareness, diagnosis, and treatment of depression [J]. Journal of general internal medicine, 1999, 14(9): 569-580.

[7] David D J, Gourion D. [Antidepressant and tolerance: Determinants and management of major side effects] [J]. L’Encephale, 2016, 42(6): 553-561.

[8] Jorm A F, Korten A E, Jacomb P A, et al. “Mental health literacy”: a survey of the public’s ability to recognise mental disorders and their beliefs about the effectiveness of treatment [J]. The Medical journal of Australia, 1997, 166(4): 182-186.

[9] Jorm A F, Medway J, Christensen H, et al. Public beliefs about the helpfulness of interventions for depression: effects on actions taken when experiencing anxiety and depression symptoms [J]. The Australian and New Zealand journal of psychiatry, 2000, 34(4): 619-626.

[10] Kessler R C, Soukup J, Davis R B, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States [J]. The American journal of psychiatry, 2001, 158(2): 289-294.

[11] Li X B, Wang J, Xu A D, et al. Clinical effects and safety of electroacupuncture for the treatment of post-stroke depression: a systematic review and meta-analysis of randomised controlled trials [J]. Acupuncture in medicine: journal of the British Medical Acupuncture Society, 2018, 36(5): 284–293.

[12] Leung M C, Yip K K, Ho Y S, et al. Mechanisms underlying the effect of acupuncture on cognitive improvement: a systematic review of animal studies [J]. Journal of neuroimmune
pharmacology: the official journal of the Society on Neuromune Pharmacology, 2014, 9(4): 492–507.

[13] Huang W, Pach D, Napadow V, et al. Characterizing acupuncture stimuli using brain imaging with FMRI—a systematic review and meta-analysis of the literature [J]. PloS one, 2012, 7(4): e32960.

[14] Liu P, Qin W, Zhang Y, et al. Combining spatial and temporal information to explore function-guide action of acupuncture using fMRI [J]. Journal of magnetic resonance imaging: JMRI, 2009, 30(1): 41-46.

[15] Hamilton J P, Farmer M, Fogelman P, et al. Depressive Rumination, the Default-Mode Network, and the Dark Matter of Clinical Neuroscience [J]. Biological psychiatry, 2015, 78(4): 224–230.

[16] Lu J, Shao R H, Hu L, et al. Potential antiinflammatory effects of acupuncture in a chronic stress model of depression in rats [J]. Neuroscience letters, 2016, 618(31–38).

[17] Park H, Yoo D, Kwon S, et al. Acupuncture stimulation at HT7 alleviates depression-induced behavioral changes via regulation of the serotonin system in the prefrontal cortex of maternally-separated rat pups [J]. The journal of physiological sciences: JPS, 2012, 62(4): 351-357.

[18] Smith C A, Armour M, Lee M S, et al. Acupuncture for depression [J]. The Cochrane database of systematic reviews, 2018, 3(CD004046).

[19] Schulz K F, Altman D G, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials [J]. International journal of surgery, 2011, 9(8): 672–677.

[20] MacPherson H, Altman D G, Hammerschlag R, et al. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): Extending the CONSORT statement [J]. Journal of evidence-based medicine, 2010, 3(3): 140-155.
[21] Battle D E. Diagnostic and Statistical Manual of Mental Disorders (DSM) [J]. CoDAS, 2013, 25(2): 191-192.

[22] Hamilton M. A rating scale for depression [J]. Journal of neurology, neurosurgery, and psychiatry, 1960, 23(56-62).

[23] Sharp R. The Hamilton Rating Scale for Depression [J]. Occupational medicine, 2015, 65(4): 340.

[24] Zung W W. A Self-Rating Depression Scale [J]. Archives of general psychiatry, 1965, 12(63-70).

[25] Chagas M H, Tumas V, Loureiro S R, et al. Validity of a Brazilian version of the Zung self-rating depression scale for screening of depression in patients with Parkinson’s disease [J]. Parkinsonism & related disorders, 2010, 16(1): 42-45.

[26] Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain [J]. NeuroImage, 2002, 15(1): 273-289.

[27] Zhao B, Li Z, Wang Y, et al. Manual or electroacupuncture as an add-on therapy to SSRIs for depression: A randomized controlled trial [J]. Journal of psychiatric research, 2019, 114(24-33).

[28] Zhang H, Xu N, Li Z, et al. [Effects on female depression treated with the combined therapy of acupuncture and the five-element music therapy] [J]. Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2018, 38(12): 1293-1297.

[29] Chen A, Gao Y, Wang G, et al. [Effect of early acupuncture intervention on post-stroke depression: a randomized controlled trial] [J]. Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2018, 38(11): 1141-1144.

[30] Li S, Li Z F, Wu Q, et al. A Multicenter, Randomized, Controlled Trial of Electroacupuncture for Perimenopause Women with Mild-Moderate Depression [J]. BioMed
research international, 2018, 2018(5351210).

[31]Lin C H, Park C, McIntyre R S. Early improvement in HAMD-17 and HAMD-7 scores predict response and remission in depressed patients treated with fluoxetine or electroconvulsive therapy [J]. Journal of affective disorders, 2019, 253(154-161).

Figures

Figure 1

the planned flowchart of the trial
Figure 2

the study schedule for enrollment, treatments, outcome measurements and data collection. HAMD Hamilton Depression Scale, SDS Self-Rating Depression Scale.

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.
